Looking for Adalimumab found 20 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Adalimumab
(Imraldi®Amgevita®Humira®)
(Injection)
|
Gastro-intestinal system - Drugs affecting the immune response - 01.05.03
|
| |
Adalimumab
(Imraldi®Amgevita®Humira®)
(Injection)
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Adalimumab
(Imraldi® Amgevita® Humira®)
(Dermatology)
|
Skin - Drugs affecting the immune response - 13.05.03
|
| |
| Non Formulary |
BNF Category |
| |
Adalimumab
(Imraldi®Amgevita® Humira®)
(Ophthalmology)
|
Eye - Other anti-inflammatory preparations - 11.04.02
|
Links Link to Drug Section  Link to document |
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis (13.05.03)
|
|
NICE TA187: Crohn’s disease - infliximab and adalimumab (01.05.03)
|
|
NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
|
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375 January 2016: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Rheumatoid arthritis - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept (10.01.03)
|
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
|
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
|
